Inflammation and Hematopoiesis: The Impact of Inflammation on the Bone Marrow Microenvironment
Inflammation has many beneficial roles in activating the immune system for defense or facilitating tissue repair, but it also shows detrimental effects if sustained chronically, i.e., might lead to HSPC damage as bone marrow failure or leukemia. This session will focus on causes and consequences of inflammation in the bone marrow and discuss potential treatment options.
This session will summarize the insights from using a genetic approach to studying patients with sterile systemic inflammatory diseases. Understanding pathogenesis led to novel treatments, several are now FDA approved and target inflammatory cytokine signaling pathways. A challenging area for the hematologist is the diagnosis and treatment of conditions with clinical and pathogenic overlap, such as hemophagocytic lymphohistiocytosis (HLH) with other inflammatory hyperferritinemic syndromes including macrophage activation syndrome (MAS). Novel insights into monogenic causes for HLH and MAS provide not only novel insights into pathogenesis but also novel treatment options.
Dr. Rebekka Schneider will summarize mechanisms which lead to an inflammatory bone marrow microenvironment and discuss how this affects normal hematopoiesis. She will pay particular attention to the process of aging which is known to involve low-grade inflammation and is also associated with age related clonal hematopoiesis and potentially malignant transformation.
Dr. Tessa Andermann will present a case of a patient with steroid-refractory GVHD and will discuss the role of fecal microbiota transplantation in the treatment. She will further discuss probiotics, and prebiotics and the effect of the microbiome on hematopoiesis and hematologic malignancies.
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members